Alizyme Latest UK Biotech Float

30 June 1996

Alizyme is the latest UK biotechnology company to seek a listing on the London Stock Exchange. The firm is floating on London's Alternative Investment Market with the aim of raising between L12 and 15 million ($18.4-$23.1 million). The flotation will give the firm a market capitalization of L20-L30 million.

The Cambridge-based firm focuses on the treatment and management of obesity and gastrointestinal disorders, and is building a product pipeline by a combination of inward licensing and in-house R&D. It will take products through to the end of Phase II clinical trials then license them out. The firm has already established a number of research or licensing agreements.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight